Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.
Primary care physicians caring for children who have been successfully treated for Cushing syndrome should continue screening for mental illness, according to data published in Pediatrics.In an NIH study, the researchers found what they called the first documented evidence of suicide ideation in a subgroup of children and adolescents in remission of Cushing syndrome.
BOSTON — In this video exclusive, Hershel Raff, PhD, professor of medicine, surgery and physiology at the Medical College of Wisconsin and scientific director and clinical research supervisor at Aurora St. Luke’s Medical Center, discusses his presentation on the laboratory diagnosis of Cushing’s syndrome. According to Raff, Cushing’s syndrome is the most enigmatic disease in endocrinology ...
Here, Lodish and Stratakis discuss the genetic mutations that give rise to Cushing syndrome, specifically those leading to the dysregulation of cAMP-dependent protein kinase A signalling. The authors also highlight how ARMC5 mutations contribute to adrenocortical hyperplasia, and discuss the role of this knowledge in patient care.
Children with Cushing syndrome may be at higher risk for suicide as well as for depression, anxiety and other mental health conditions long after their disease has been successfully treated, according to a study by researchers at the National Institutes of Health.
(HealthDay)—In a case report published online April 7 in Pediatrics, iatrogenic Cushing's syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.
Yes, Harvey Cushing MD was a Neurosurgeon Most people in medicine are acquainted with the name Cushing, but it is not widely known that he was a Neurosurgeon. And he even rubbed shoulders with other surgical gods, like Osler and Halsted. Slaven Gojkovic, and 3rd year medical student in Croatia, […]
HARRISBURG, Pa. (PRWEB) April 08, 2016 Hoping to help other Cushingâs disease patients and their families, Marie Conley releases her funny, intimate and emotional email exchanges with family and friends in the new book, â A Cushingâs Collection: A Humorous Journey Surviving Cushingâs Diseas...
DUBLIN, Ireland and TREVOSE, Pa., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP) today announced that the United States Patent and Trademark Office (USPTO) issued a patent related to the Company's lead investigational drug candidate, COR-003 (levoketoconazole), a cortisol inhibitor that is currently being studied in a global Phase 3 trial for the treatment of endogenous...
* Latest Cushing crude stocks above 67.5 mln bbls - Genscape data
BOSTON — Maria Fleseriu, MD, FACE, professor of medicine and neurologic surgery at Oregon Health Sciences University, discusses her presentation on Cushing’s disease and treatment selection. According to Fleseriu, even 100 years after the discovery of Cushing’s disease, clinicians still struggle with late diagnosis of patients.
MENLO PARK, CA -- (Marketwired) -- 12/14/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating activity at the glucocorticoid receptor (GR), presented initial efficacy data from its Phase 1/2 trial of mifepristone in combina...
H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively low […]
MENLO PARK, CA -- (Marketwired) -- 01/28/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its preliminary financial results for t...
MENLO PARK, CA -- (Marketwired) -- 04/28/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today released data supporting the clinical advancement of its proprietary, selective cortisol modulator...
MENLO PARK, CA -- (Marketwired) -- 03/01/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its financial results for the fourth qu...
Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday. Strongbridge is an endocrinology-focused company, pursuing an acquisition model to build a diversified orphan-drug platform. “With a focus on rare endocrine diseases – Cushing’s syndrome and acromegaly [R...
Within most families, the experience of having a member with Down syndrome is generally a positive one, new research concludes. Investigators evaluated surveys of more than 2,000 parents or guardians of individuals with Down syndrome; more than 800 siblings of someone with Down syndrome, and 248 people with Down syndrome.
Michael Cushing, a personal injury attorney at Cushing Law Offices, recently settled a wrongful death lawsuit (Case No. 12 L 897) on behalf of the family of a woman who died from drug intoxication that included Fentanyl, and a combination of other drugs. Chicago, IL (PRWEB) January 05, 2016 The wrongful death lawsuit, Fred Saltzman, as Special Administrator of the Estate of Tenessa Vincent, decea...
On Thursday, November 5, 2015, Corcept Therapeutics (CORT) announced its results for Q3 2015 and held a conference call.
On April 28, 2016, Corcept Therapeutics (CORT) announced an update of its next generation, selective GR antagonist: CORT125134. Launched Phase I/II Trial of CORT125134 to treat solid tumors Will launch Phase II Trial of CORT125134 to treat Cushing’s syndrome in Q2-2016 Underscored CORT125134’s promising profile as seen in animal m...
On Thursday, January 28, 2015, Corcept Therapeutics’ (CORT), Corcept will release preliminary Q4-2015 results and provide guidance and corporate update. Since 2014, Corcept has been providing a major update in January. The conference call details are below:When: 5:00pm, January 28, 2015Phone: 1-888-771-4371 (USA) & 1-847-585-4405 (International)  ...
Takotsubo, c'est le nom d'un piège à poulpes japonais*. Sa forme a inspiré le nom du syndrome de Takotsubo. Un syndrome généralement provoqué par des facteurs de stress négatifs tels que la douleur, la colère, la peur : c'est le « syndrome du cœur brisé ».